The Pathway Menopause Forgot: What a Quiet Penn State Trial Is Telling Women Whose Cholesterol Just Started Drifting

After her 56th birthday, my sister’s cholesterol jumped 32 points overnight. Her doctor said “let’s keep an eye on it.” What he didn’t say is that her body had just lost the pathway that was protecting her for forty years — and that a randomized controlled trial published last year had quietly identified a second, food-based route the medical world is only now beginning to discuss.

My sister called me from the parking lot of her doctor’s office. She had just turned 56. Her annual physical had taken seven minutes. Her cholesterol had jumped from 198 to 230 in the twelve months since her last appointment, even though she hadn’t changed a single thing about how she ate or moved or slept. Her blood pressure had crept from 118/76 to 132/84. Her doctor had said the words she’d been quietly bracing for ever since our mother died at 67: “Let’s keep an eye on it. If it doesn’t come down in six months, we’ll talk about a statin.”

Then she got into her car and Googled “statin side effects” for an hour.

She is not the kind of woman who panics. She runs an emergency department. She has watched men in their fifties code on her trauma bay, and she has watched women in their sixties dismissed for hours before someone finally caught the troponin and figured out it was a heart attack and not anxiety. She knows the numbers. She knows what comes next if she doesn’t do something now.

What she didn’t know — and what nobody, in any of her seven-minute appointments since menopause, had ever explained to her — was why her numbers had suddenly started drifting at all.

She had done everything right. She had walked. She had cut alcohol. She had switched to olive oil years ago. She had her bloodwork done annually. And somewhere between her 53rd birthday and her 56th, her cardiovascular numbers had quietly stopped behaving the way they had behaved for forty years — and no one had told her why.

This article is what I learned trying to answer her question.

It turns out the answer was hiding in a 2024 randomized controlled trial out of Penn State, in a Nobel Prize from 1998, and in a single, unsexy molecule that almost every postmenopausal woman is losing the ability to make — without ever being told.

What she tried first — and why none of it touched the number

Before she came to me, my sister had spent a year trying to fix the cholesterol number on her own. She wasn’t ready for a statin. She had a friend who’d been on atorvastatin for six months and had stopped remembering names at meetings. The friend called it “the fog.” My sister, who has spent thirty years building a career on being the sharpest person in the room, was not going to be the one who couldn’t remember names at meetings.

So she had tried the things you try.

She tried a menopause supplement. A friend had recommended Bonafide. She ordered it. She took it for three months. It was, by every account, a fine product — but it was aimed at hot flashes, which she didn’t really have, and it did nothing for the number on her lipid panel, which was the only thing she actually cared about.

She tried beetroot powder. The one with the cardiologist on the box. She mixed it into water for two weeks. It tasted, in her words, “like dirt that someone had run through a sock.” The sugar load was higher than she’d realized. After fourteen days she put the canister in the back of the pantry where it still sits today.

She tried CoQ10. She tried fish oil. She added more leafy greens. She walked an extra mile a day. At her six-month follow-up, the cholesterol had come down two points. The blood pressure was the same.

And then she did the thing the smartest patients always do eventually, which is she stopped trying to fix the symptom and started trying to understand the mechanism.

The conversation that changed everything

She called me on a Saturday morning. She had been reading Peter Attia’s Outlive. She had listened to Mary Claire Haver’s podcast for the better part of a week. She had read most of Lisa Mosconi’s The Menopause Brain. And she had finally arrived at a single sentence, in a single paragraph of a 2024 American Heart Association statement, that explained more about what was happening in her body than any of her doctors had explained in seven years.

The sentence, paraphrased: The menopause transition is associated with adverse changes in body composition, lipids, vascular function, and blood pressure — and the underlying biology of these changes is, to a meaningful degree, the loss of estrogen’s direct support of the cardiovascular system.

She read it to me over the phone. Then she said, “Why has nobody ever said that to me? In all of these appointments. In all of this Googling. Why did I have to go find this in a clinical statement?”

I didn’t have a good answer.

What I did have, after a week of reading, was a story about a molecule that almost nobody is talking to women in their fifties about. And a 2024 trial that should have been on the cover of every women’s health magazine in the country, and instead has stayed politely buried in the pages of Frontiers in Nutrition.

A 1998 Nobel Prize most postmenopausal women have never heard of

In 1998, the Nobel Prize in Physiology or Medicine went to three American researchers — Robert Furchgott, Louis Ignarro, and Ferid Murad — for a discovery that, on paper, sounds boring enough to skip past.

They had identified that the body produces a tiny, short-lived molecule called nitric oxide, and that this molecule signals blood vessels to relax. It is, in effect, the body’s own internal vasodilator. When a healthy artery needs to widen — to let blood through, to carry oxygen, to keep pressure in a reasonable range — it releases nitric oxide, and the vessel relaxes.

It took the Nobel committee almost a century to recognize this. The molecule itself had been hiding in plain sight in the body since the day the first human walked the earth. But because it was so small, so short-lived, and so easy to miss in the lab, nobody had figured out what it did until the 1980s.

What almost nobody outside cardiology heard about, even when the Nobel was announced, was an older story. In 1896, Alfred Nobel himself — the man who invented dynamite, the man whose name is on the prize — was prescribed nitroglycerine by his physician for the chest pain that would eventually kill him. He refused to take it. He thought it absurd that the explosive compound from his own factory could also be a medicine.

He died, in part, from the very condition the nitroglycerine could have eased. His own body had stopped making enough of the molecule his own invention happened to release.

A century later, the Nobel committee gave the prize to the men who finally explained what was happening inside Alfred Nobel’s chest. And almost nobody noticed.

Two pathways. One closes at menopause. The other doesn’t.

Here is the part that, when my sister read it, made her sit down at her kitchen table and stare at the wall for ten minutes.

The body has not one, but two ways to make nitric oxide.

The first pathway — the one that runs for most of an adult’s life — is called the L-arginine / eNOS pathway. The body takes the amino acid arginine, runs it through an enzyme called endothelial nitric oxide synthase (eNOS), and produces nitric oxide directly inside the lining of the blood vessels.

That enzyme — eNOS — runs on estrogen. Estrogen is one of its most important activators. When estrogen is around in normal premenopausal levels, eNOS hums along, the body makes plenty of nitric oxide, and the cardiovascular system stays well-supported.

And then, somewhere between a woman’s late forties and her mid-fifties, the ovaries stop producing estrogen.

The fuel runs out. eNOS slows down. The primary nitric oxide pathway dims.

And this — not weight, not diet, not exercise, not stress — is the single most under-discussed reason that postmenopausal women suddenly see their cholesterol numbers move, their blood pressure creep, their arterial stiffness measurably increase. The pathway that was quietly protecting them for forty years has lost its main driver.

But there is a second pathway. And it does not depend on estrogen.

This second pathway is sometimes called the entero-salivary nitrate pathway. The body takes dietary nitrate from food — the kind concentrated in beets, dark leafy greens, and a small handful of other plants — routes it through the saliva and the gut, and converts it stepwise into nitrite, and then into nitric oxide. The same molecule. The same protective signaling. A completely different route to get there.

Estrogen is not required. The endothelium is not required. You just need the dietary nitrate.

The Karolinska Institute in Sweden, working largely under researchers Jon Lundberg and Eddie Weitzberg, has been mapping this second pathway since the late 1990s. The papers were technical. They sat outside the mainstream cardiology conversation for the better part of two decades. They were, in effect, hidden in plain sight — the way nitric oxide itself had been hidden in plain sight in the body for a century.

And then, in June 2024, a research team at Penn State did the trial almost nobody had bothered to do.

This is not a fitness study on twenty-something men in a gym. This is not an observational study trying to correlate vegetable intake with later mortality. This is a randomized, double-blind, placebo-controlled trial. The same women received both the nitrate and the placebo, in random order, and the researchers measured what changed in their blood vessels over seven days.

The nitrate worked. The placebo didn’t.

And it worked specifically in the population almost nobody had bothered to study before: postmenopausal women, the very group that had lost the estrogen-dependent pathway and had been left without a clear, food-based answer for what to do next.

What this means if you’re the woman whose doctor just said “let’s keep an eye on it”

It means your habits didn’t change. Your body did.

It means the drift in your cholesterol and your blood pressure is not a failure of willpower. It is not because you stopped trying. It is not because you started eating differently or sleeping less or getting older in some vague, generic way. It is because the specific molecular pathway that has been protecting your cardiovascular system for forty years has lost its primary driver, and almost nobody in primary care has the appointment time — or, frankly, the training — to explain that to you.

It means there is a second pathway your body still has. It does not require estrogen. It runs on food.

It means that, in a 2024 randomized controlled trial, postmenopausal women who supported that second pathway for seven days saw measurable improvements in blood vessel function compared to the same women on a placebo.

And it means the smartest thing my sister could do — before her next physical, before the statin conversation, before another six months go by — was figure out how to actually deliver that dietary nitrate, daily, in a form she would actually take, in a dose that actually matched the research.

Which turns out to be harder than it sounds.

Why the beetroot aisle is mostly a trap

She went looking. So did I.

What we found was a category of beetroot products that were, in most cases, not built for her.

Most were powders. They tasted, as she had already discovered, like something a child would refuse. Several of the most popular brands listed the weight of the powder on the front of the bottle — the “6000 mg beetroot” sticker — but never standardized the actual dietary nitrate content, which is the only thing that matters for the second pathway. You can have a kilogram of beetroot powder and almost no nitrate in it, depending on the soil it grew in, the variety, the processing, the heat exposure during drying.

Many were loaded with sugar to mask the earth taste. Several were aimed primarily at men — bodybuilders, weekend cyclists, “pump” products with cartoon labels.

And almost none of them were built for the specific woman who was reading the Penn State paper at her kitchen table on a Saturday morning and trying to figure out what to do on Monday.

The capsule we ended up choosing

What my sister wanted — what I think most women in her position want — was something specific. A daily capsule. No powder. No sugar. No mixing. No tongue-turns-blue moment. Standardized for the dietary nitrate dose that matched the published research, not the marketing weight of the powder. Third-party tested for what was actually in the bottle. Made for women in midlife. Sold by a company that wasn’t embarrassing.

She found one. It is the only one I can comfortably recommend to her, to my own wife, or to the half-dozen women I know in their fifties who have texted me a version of the same question in the last year.

It’s called Purevia Beetroot.

Purevia Life Beetroot Capsules · 1300mg · 60 Capsules · Nitric Oxide Support · Clinically Inspired Formula

Three things made the difference for her.

First, the standardization. Purevia is built around dietary nitrate content, not powder weight. The dose is set to align with the level used in postmenopausal cardiovascular research, not what looks good on a label. That alone disqualifies most of the bottles on the supplement shelf.

Second, the format. It’s a capsule. Two capsules a day with water. No taste. No sugar. No mixing. No staining. No 3 PM mess on the kitchen counter. She has been on it long enough now to confirm that the part she dreaded most about beetroot — the taste, the powder, the daily friction — was, with this, simply not part of the experience.

Third, the testing. Each batch is third-party tested for both the actual dietary nitrate content and for heavy-metal contamination, which is a real and under-discussed issue with root-vegetable supplements grown in soils that aren’t carefully sourced. The certificate of analysis is available on request.

How it compares to what’s on the shelf

What the women I know have said

I’ve had this conversation enough times now to have a small, informal sample of women in their fifties who have made the same decision my sister did. The pattern is consistent. Below are three of them, in their own words. They asked that I use first names only.

Individual experiences will vary. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

What I’d tell you if you were my sister

I would tell you, first, that this is not a magic pill. There is no magic pill. The Penn State trial measured a marker of vascular function in seven days. Your body is on a longer arc than that. The women I know who’ve taken it the longest have been on it for six to nine months. They’ve watched their next physical, and then the one after that. Some have seen the lipid numbers stabilize. Some have seen them come down. Some haven’t kept track. They’ve stayed on it because of how it feels to do something real for the second pathway, instead of nothing.

I would tell you that supporting the second nitric oxide pathway is not a replacement for working with your doctor on the rest of your cardiovascular plan. It is not a statin. It is not a substitute for blood pressure medication if you need it. It is not hormone therapy. It is a daily, food-based way to support a specific pathway that estrogen used to support, and that the published research suggests can still be supported through diet and standardized supplementation after estrogen is gone.

And I would tell you that if you’re going to try it, the dose, the standardization, and the testing are the things that actually matter — not the powder weight, not the picture on the front of the bottle.

The version I recommend, the version my sister has been on for almost a year now, is below.

Her next lipid panel is in three weeks. I’ll know what it says when she does. What I already know is that, for the first time since menopause, she is no longer sitting in the parking lot after her appointments wondering what changed and why nobody is explaining it to her.

She is the one who made the move.